Spectrum Pharmaceuticals

$1.36 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company operates through developing and commercializing oncology and hematology drug products segment. It focuses on developing ROLONTIS and POZIOTINIB. ROLONTIS is being investigated for the treatment of chemotherapy-induced neutropenia. POZIOTINIB is an oral pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR, HER) Family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations.

Stock Analysis

last close $1.21
1-mo return 47.6%
3-mo return 65.2%
avg daily vol. 1.72M
52-week high 2.53
52-week low 0.6
market cap. $191M
forward pe -
annual div. -
roe -155.7%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 40.2%

Subscribe now for daily local and international financial news